Archive for category Pharma
The delivery of Theresa May’s letter to European Council president Donald Tusk triggering Article 50, and the official start of the UK’s two-year process of negotiating its divorce from the EU, made the choice of this month’s PME cover an easy one.
Inside the issue there’s a great look at the implications of Brexit for pharma, with Nicola Maguire from law firm Cooley LLP rounding up the industry’s areas of concern, Alexa Forbes from Four health Communications asks ‘can UK pharma rise to the post-Brexit challenge’ and greyhealth group’s Paul Hughes looks at the facts (and the alternative facts) of the situation.
Meanwhile, in a series of exclusive interviews with PME, Japanese pharmaceutical companies pull no punches when it comes to what the reassurance they want from the UK on its future in science and innovation. Read the rest of this entry »
You won’t generally find PME issues following a particular theme each month – there’s simply too much interesting ground to cover in the magazine for that.
Nevertheless, as each issue coalesces there are often common strands across different features and such seemed the case with March’s PME, which contains a nice chunk of ‘careers’ content. Read the rest of this entry »
In this month’s issue of PME magazine we balance the changes that are already the theme of 2017 with some much needed stability in the form of a look at family-owned or foundation-run pharmaceutical companies.
Such European businesses include Germany’s Boehringer Ingelheim, Italy’s Chiesi and Denmark’s LEO Pharma, whose president and CEO Gitte Aabo talked to us about playing the long game and how this sees it through times of boom and bust. Read the rest of this entry »
At almost 310 metres high The Shard is the tallest building in the capital, towering over its London neighbours in Southwark.
One of those in its shadow is the site for what will become Science Gallery London, an exhibition and performance space that, from 2018, hopes to connect scientific researchers, students, local communities and artists. Read the rest of this entry »
As PME‘s first issue of the year comes out the European pharmaceutical industry goes into 2017 steeling itself for the start of Brexit, with plenty of words already devoted to what we don’t know about the implications of the UK’s vote to leave the European Union.
This year should see the phony war end and hostilities begin in earnest when the UK formally triggers Article 50 and commences the official process of withdrawing from the EU. Read the rest of this entry »
In screenwriting the three-act structure progresses from setup to confrontation to resolution, with the first act used for establishing the main characters.
It’s a device for fiction of course, but much of this year feels like just that. In fact, looking back on the last 12 months, 2016 also feels like a setup for events yet to come. Read the rest of this entry »
This month in PME we hear from the European Commissioner for Health on the burden European countries face from chronic diseases.
Dr Vytenis Andriukaitis tells of his concern about the growth in conditions such as cardiovascular diseases, cancer and type 2 diabetes, and how EU Member States need to be supported if they are to be tackled. Read the rest of this entry »